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Summary 
Embryonic stem cells (ESCs) can instruct the conversion of differentiated cells toward 
pluripotency following cell-to-cell fusion by a mechanism that is rapid but poorly understood. 
Here, we used centrifugal elutriation to enrich for mouse ESCs at sequential stages of the cell 
cycle and showed that ESCs in S/G2 phases have an enhanced capacity to dominantly 
reprogram lymphocytes and fibroblasts in heterokaryon and hybrid assays. Reprogramming 
success was associated with an ability to induce precocious nucleotide incorporation within 
the somatic partner nuclei in heterokaryons. BrdU pulse-labeling experiments revealed that 
virtually all successfully reprogrammed somatic nuclei, identified on the basis of Oct4 re-
expression, had undergone DNA synthesis within 24 hr of fusion with ESCs. This was 
essential for successful reprogramming because drugs that inhibited DNA polymerase 
activity effectively blocked pluripotent conversion. These data indicate that nucleotide 
incorporation is an early and critical event in the epigenetic reprogramming of somatic cells 
in experimental ESC-heterokaryons. 
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Introduction 
Epigenetic reprogramming is a feature of normal embryonic development (Feng et al., 2010) 
that can also be induced experimentally using a range of strategies (Gurdon and Melton, 
2008; Yamanaka and Blau, 2010). For example, differentiated somatic nuclei can regain 
pluripotency upon injection into oocytes (nuclear transfer) or through the forced expression 
of specific combination of transcription factors that induce a pluripotent stem (iPS) cell state 
(Gurdon, 1960; Takahashi and Yamanaka, 2006). Conversion of somatic cells toward 
pluripotency is associated with distinctive changes in the chromatin and DNA methylation 
status of the somatic genome (Deng et al., 2009; Simonsson and Gurdon, 2004) thought to be 
important for stable re-expression of core pluripotency factors such as Oct4, Sox2, and 
Nanog (reviewed by Papp and Plath, 2011). A third strategy for reprogramming somatic cells 
is by cell-cell fusion. There is an accumulating literature describing fusions between 
embryonic stem cells, embryonic carcinoma (EC) and embryonic germ (EG) cell lines with 
somatic cell partners such as thymocytes, lymphocytes, fibroblasts, or hepatocytes derived 
from the same or a different species (Miller and Ruddle, 1976; reviewed by Soza-Ried and 
Fisher, 2012). Collectively, these experiments have shown that somatic nuclei can be 
reprogrammed to acquire the epigenetic and developmental properties of their pluripotent 
partner (Ambrosi et al., 2007; Cowan et al., 2005; Do et al., 2007; Foshay et al., 2012; 
Matveeva et al., 1998; Pereira et al., 2008; Tada et al., 1997, 2001; Tat et al., 2011). Although 
the molecular mechanisms that determine the success and direction (or dominance) of this 
conversion are not fully understood, complete reprogramming is achieved 5–7 days after 
fusion with ESC, EG, and EC cells and is thought to occur in two steps. First, transient 
heterokaryons are formed in which both parental nuclei remain spatially discrete but share a 
common cytoplasm. Low levels of pluripotent gene expression from the somatic partner are 
initiated in a proportion of heterokaryons and increase over a 3–4 day period before the 
parental nuclei fuse to generate hybrids (Pereira et al., 2008). This second step has been 
proposed to stabilize or “fix” newly acquired gene expression profiles, enabling the resulting 
tetraploid cells to generate pluripotent colonies (reviewed by Serov et al., 2011). Because the 
first step occurs in the absence of cell division, it has been generally assumed that DNA 
synthesis is not required to initiate reprogramming. 
Although some evidence supports this view (Bhutani et al., 2010), other studies have 
suggested that DNA synthesis may be required to reverse cis-mediated silencing of genes 
such as Oct4 and Nanog (Foshay et al., 2012) or have suggested that somatic genome 
reprogramming occurs during the first cell cycle (Han et al., 2008). In this regard, classic cell 
fusion experiments performed more than 40 years ago using HeLa cells (Rao and Johnson, 
1970) had shown that early (or precocious) DNA synthesis is induced in G1-phase cells upon 
fusion with cells at later stages of the cell cycle (in S or G2 phases). As DNA synthesis 
provides an unrivaled opportunity for chromatin and nucleosome remodeling as well as 
changes to DNA methylation, it is important to establish whether there is any involvement of 
DNA synthesis in heterokaryon-mediated reprogramming in order to understand the 
mechanisms behind this conversion. 
Embryonic stem cells and the pluripotent cells of the epiblast from which they arise, have a 
very unusual cell-cycle structure characterized by a short cell-cycle time, truncated G1 phase, 
and a large proportion of cells in DNA synthesis (S) phase (Fluckiger et al., 2006; White and 
Dalton, 2005). Pluripotent cells in the mouse epiblast devote more than 50% of cell-cycle 
time to S phase and a similarly high proportion of mouse ESC, EG, and EC cells (35%–50%) 
are reported to be in S phase (Savatier and Afanassieff, 2002; Stead et al., 2002). This 
unusual profile is associated with high levels of Cdk activity and anaphase-promoting 
complex/cyclosome (APC/C) substrates present throughout the cell cycle (Fujii-Yamamoto 
et al., 2005; Koledova et al., 2010b; Yang et al., 2011). A recent report has suggested that 
Cdk activity in ESCs may oscillate in a manner that is muted as compared with differentiated 
or somatic cells (Ballabeni et al., 2011). Although the biological consequences of this unusual 
cell cycle are not known, evidence that ESCs loose this profile upon differentiation (Bar-On 
et al., 2010; Calder et al., 2013; Koledova et al., 2010a; Orford and Scadden, 2008) and 
conversely, that somatic cells regain it when reprogrammed (Ghule et al., 2011; Ruiz et al., 
2011; Singh and Dalton, 2009), have suggested that it may be important for rapid self-
renewal of pluripotent cells. 
One of the consequences of ESCs having impaired or muted cell-cycle checkpoints is that 
many of the drugs that have been traditionally used to synchronize or block somatic cells at 
specific stages of the cell cycle are often either ineffective or promote differentiation in 
ESCs, rendering cell-cycle studies in undifferentiated ESCs problematic (Calegari and 
Huttner, 2003; Han et al., 2008; Neganova and Lako, 2008; Ruiz et al., 2011). To circumvent 
this, we have optimized a biophysical cell separation method to enrich for ESCs in discrete 
phases of the cell cycle. Using this methodology we asked whether the ability of ESCs to 
dominantly reprogram differentiated cells was influenced by their cell-cycle stage. Our 
results show that ESCs in late S/G2 phases of the cell cycle have a markedly enhanced ability 
to reprogram somatic cells and provide evidence that this is because they induce the somatic 
nucleus to undergo a round of precocious DNA synthesis shortly after fusion. 
 
Results 
Cell-Cycle Synchronization of ESCs by Centrifugal Elutriation 
Counterflow centrifugal elutriation allows the separation of heterogeneous cell populations 
into fractions of uniform size and density (Banfalvi, 2008). As size and density reflect cell-
cycle stage, we used this approach to isolate mouse ESCs at sequential stages of the cell cycle 
from undifferentiated cultures. Briefly, single cell suspensions of E14 ESCs were loaded into 
an elutriation chamber and centrifuged at constant speed. Fractions were collected at 
increasing flow rates (6–17 ml/min, F8 to F16) and evaluated for their DNA content by 
staining with propidium iodide (PI) followed by fluorescence-activated cell sorting (FACS) 
analysis. Typical DNA content profiles of unsynchronized ESCs and of sequential elutriated 
fractions are shown in Figure 1A (top and bottom panels, respectively) where the gates used 
to define G1, G2, and S phase are marked. Fractions F8 and F9 contained predominantly G1-
phase ESCs (>80%), and fraction 16 was enriched for cells in G2 (>70%), whereas S-phase 
cells centered around fraction F12. The consistency of this separation approach was 
confirmed in five independent experiments (Figure S1A available online). To quantify cells 
undergoing DNA synthesis within each fraction we also subjected samples to a 45 min pulse 
of BrdU (100 μM) after elutriation and then identified and scored BrdU incorporating cells 
using immunofluorescence microscopy, as illustrated in Figure 1B (anti-BrdU, green). 
Among undifferentiated asynchronous ESC cultures BrdU label was routinely detected in 
∼35% of cells and the pattern of BrdU distribution within nuclei was similar to the patterns 
previously reported for S-phase stages in somatic cells (Azuara et al., 2003; McNairn and 
Gilbert, 2003), as shown here for human B cells (hB) (Figure 1B and legend). In particular, 
early S phase (I, II) and late S phase (IV, V) patterns were detected in 42% and 20% of 
BrdU-labeled mouse ESCs and characteristically marked DNA replication at either diffuse 
euchromatic sites or within blocks of heterochromatin, respectively. Mid-S-phase cells (III) 
accounted for the remaining 38% of BrdU-labeled cells in which DNA synthesis was focused 
at either perinuclear domains (a), perinucleolar sites (b) or within dispersed sites of DAPI-
intense heterochromatin (c). Using this BrdU pulse-labeling strategy we enumerated S-phase 
cells within elutriated ESC samples (Figure 1C). Fractions F11 to F12 were enriched for S-
phase cells (>60% of cells incorporated BrdU, consistent with previous PI staining profiles). 
Fractions F8 and F9 contained relatively few S-phase cells (8%–14%) with labeling patterns 
indicative of early S phase (I and II). Fraction F16 typically contained 20%–30% BrdU 
positive cells and these cells showed a typical late S-phase distribution pattern (IV and V). 
 
Figure 1 
Separation of Mouse ESCs According to Cell-Cycle Stage Using Counterflow Centrifugal 
Elutriation 
(A) Unsynchronized mouse E14tg2A ESCs cells were subjected to counterflow centrifugal 
elutriation and sequential fractions (F8, F9, F12, F13, F16, denoting flow rates) were stained 
with propidium iodide (PI) to assess DNA content by FACS. Gates used to define cells in G1, S, 
or G2/M are indicated in the top panel. 
 
(B) BrdU labeling patterns that characterize successive stages of S phase in human B (hB) and 
mouse ESCs (mESC) are shown. Early S (I) phase is distinguished by a fine diffuse labeling of 
multiple euchromatic sites that gradually increase in number and intensity by stage II. Mid S 
phase (III) shows BrdU incorporation at the nuclear periphery (IIIa) and outlining nucleoli (IIIb), 
and in ESCs a pronounced increase in the overall number of foci (IIIc). In later stages (IV and V) 
large constitutive heterochromatin domains are evident. Scale bars, 5 μm. 
 
(C) The abundance of S-phase cells in each elutriated fraction was determined by BrdU pulse 
labeling (45 min, 100 μM) and anti-BrdU immunostaining. 
 
(D) Mouse ESCs enriched for G1 using counterflow centrifugal elutriation (F9) were cultured for 
1–3 days to monitor progression through the cell cycle following elutriation. Unsynchronized ES 
cells are provided for comparison (in gray) 
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Enrichment and Viability of Mouse ESCs after Cell-Cycle Separation Using Counterflow 
Centrifugal Elutriation, Related to Figure 1 
(A) Histograms show the proportion of ESCs corresponding to G1 (gray), S (black) and G2 
(white), summarizing 5 independent elutriation experiments. The PI-staining profiles and 
gates used to define cells at different cell-cycle stages are indicated in Figure 1A. 
 
(B) Unsynchronized (gray histograms) or ESCs enriched for G1, S or G2/M phases of the 
cell cycle (open histograms) were cultured for up to 3 hr in suspension in media containing 
LIF and viability was analyzed using trypan blue exclusion. Results show the mean and SD 
of four independent experiments. 
As drug-based treatments that arrest or delay ESC cell-cycle progression have been reported 
to promote differentiation and cell death (Burdon et al., 2002; Calegari and Huttner, 2003; 
Neganova and Lako, 2008; Orford and Scadden, 2008; Ruiz et al., 2011) we asked whether 
elutriated ESC samples successfully resumed cell cycle upon reculture. Fractions F8/F9, that 
were relatively homogeneous and enriched for G1-phase ESCs, were monitored for cell-cycle 
progression using PI staining at successive culture times (Figure 1D). G1-enriched ESC 
samples (F9, day 0) progressed through to S (day 1) and G2 (day 2) phases of the cell cycle, 
and subsequently showed a PI profile that resembled nonsynchronous ESC cultures (day 3). 
No increase in cell differentiation or significant loss of cell viability was detected in these 
cultures throughout the time course. Furthermore, a direct comparison of cell survival in 
nonsynchronous, G1-, S-, and G2/M-enriched ESCs cultured immediately after elutriation 
showed a similar viability between fractions (Figure S1B). 
ESC Reprogramming Capacity Varies with Cell-Cycle Stage 
A previous study of hybrids generated between mouse thymocytes or fibroblasts fused with 
mouse ESCs that had been grown to different degrees of confluence (Sullivan et al., 2006) 
had suggested that reprogramming could be optimized using stem cells enriched for G2/M 
phases of the cell cycle. We used counterflow centrifugal elutriation to isolate cell-cycle 
stages from other variables that may occur in cultures grown to different densities. The ability 
of elutriated ESC samples to stably reprogram mouse B lymphocytes was compared using 
puromycin resistant mouse B cell targets that carried a silent Oct4-GFP transgene 
(GOF18ΔPE) (Yeom et al., 1996). These cells were fused in a 1:1 ratio with unsynchronized 
or elutriated mouse ESC fractions and the resulting cells were plated at limiting dilution in 
drug-containing media for 12 days as described previously (Pereira et al., 2010) (Figure 2A). 
Puromycin-resistant hybrid colonies expressing alkaline phosphatase (AP+, Puro+) were 
enumerated and compared to values obtained with nonsynchronized ESCs (Figure 2B). In 
parallel, some colonies were expanded to evaluate Oct4-GFP expression, DNA content, 
karyotype, and the potential of the resulting hybrid cells to differentiate. This analysis 
indicated that S/G2-enriched fractions of mouse ESCs (F13) generated at least 5-fold more 
pluripotent hybrid colonies than G1-enriched fractions (F8) and supported the idea that ESCs 
at later stages of cell cycle have a more potent reprogramming capacity. This enhanced 
reprogramming (Figure 2B; Table S1) was not a reflection of intrinsic differences in the 
survival, cloning or fusion efficiency of S/G2, as shown in control experiments (Figures S2A 
and S2B). Importantly, hybrid clones generated by fusing mouse B cells with either 
unsynchronized or G2-enriched ESC re-expressed the Oct4-GFP transgene robustly (Figures 
S2C and S2D), were tetraploid (Figure S2D) and able to differentiate upon LIF withdrawal 
into mesoderm, endodermal, and ectodermal cell types (as exemplified by clones 1,6, and 
3,10, respectively; Figures S2D–S2F). Consistent with full reprogramming of hybrid cells, a 
bisulfite analysis of DNA methylation showed a near complete loss of methylated CpG 
residues across endogenous mouse Oct4 alleles by day 21 (Figure 2C). To estimate when 
after fusion this reprogramming-associated loss of DNA methylation had occurred, we next 
performed bisulfite analysis of the promoter region of the somatically derived Oct4-GFP 
transgene. This region is heavily methylated in the parental mouse B cells (97%, Day 0) but 
hypomethylated in reprogrammed hybrids (2% methylation, day 21). Time course 
experiments revealed that DNA demethylation of the reporter was evident as early as 3 days 
after fusion (Figure 2D), consistent with previous studies showing that Oct4 activation is an 
early event required for ESC fusion-mediated reprogramming (Han et al., 2008; Pereira et al., 
2008). 
  
Figure 2 
 
ESCs at Late Stages of the Cell Cycle Are More Efficient at Reprogramming B Cells Than 
Unsynchronized ESCs or G1-Phase Cells 
(A) Strategy used for generating hybrids between mESCs (enriched in G1, S, S/G2, or G2/M) 
and puromycin-resistant (Puro+) mouse B cells (mB) derived from an Oct4-GFP transgenic 
line (GOF18ΔPE) (Yeom et al., 1996). B cells were predominantly in G1 (≥75%), as judged by 
PI staining. Successfully fused cells were plated in media supplemented with puromycin for 21 
days. Immediately following cell fusion, the parental mESC and mB nuclei remained discrete 
within a single cell body supported by a shared cytoplasm for up to 3 days. Subsequently, the 
nuclei fuse giving rise to a proportion of stable proliferating hybrid cells resistant to puromycin 
and positive for alkaline phosphatase activity and Oct4 expression. 
 
(B) Reprogramming efficiency of ESCs at different cell-cycle stages was evaluated by scoring 
the number of Puro-resistant hybrid colonies positive for AP activity (AP+). Results show the 
number of AP+ colonies expressed relative to colonies obtained with unsynchronized mESC 
(shown as 1), where error bars represent the SD of two to three independent experiments and 
asterisks denote statistical significance (p < 0.05, t test). 
 
(C and D) DNA methylation at the endogenous (mCHr17) (C) and transgenic (GOF18ΔPE) 
(D) Oct4 locus in hybrid cells was assessed by bisulfite sequence analysis, where closed circles 
represent methylated CpG and open circles show unmethylated CpG. In (D) the kinetics of loss 
of DNA methylation at the B cell derived transgenic Oct4 locus was monitored using a 
previously described approach and primers (Han et al., 2008) and the percentage values 
indicate the proportion of CpG methylated sequences. 
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Characterization of Reprogrammed mB × mESC Hybrid Clones, Related to Figure 2 
(A) Fusion efficiency was determined using H2B-mCherry mouse ESCs and human B cells 
labeled with carboxylfluorescein diacetate succinimidyl ester (CFSE). The frequency of 
double labeled cells was determined by FACS analysis and the fusion efficiency of different 
ESC cell-cycle fractions (open histograms) relative to unsynchronized samples (gray 
histogram) are indicated. Mean and SD of 3 independent experiments are shown. 
 
(B) The viability of cells immediately after elutriation and 24 hr after PEG-mediated cell 
fusion was compared by trypan blue exclusion. Results show the mean and SD of 3 
independent experiments. 
 
(C) Hybrid reprogrammed clones were generated by fusing puromycin-resistant mB cells 
(derived from GOF18ΔPE) with G2-enriched or asynchronized ESCs. Colonies of puromycin 
resistant, GFP+ reprogrammed cells were isolated and expanded for 30 days in culture. 
 
(D) DNA content and GFP expression was assessed by FACS. Metaphase spread analysis of 
these clones indicated similar average chromosome content (76 to 80), consistent with a 
broadly tetraploid status. 
 
(E) Hybrid clones generated with unsynchronized (open histograms) or G2-enriched ESCs 
(gray histograms) were subjected to LIF withdrawal and the expression of several 
differentiation–associated genes was confirmed by qPCR. Error bars indicate the SD of two 
to three independent experiments. 
 
(F) Confocal images showing the expression of pluripotent (Oct4), or of ectodermal (Nestin, 
Tuj1), endodermal (Gata6) and mesodermal (CD44) associated genes by hybrid clones 
(generated with unsynchronized or G2-enriched ESCs) before (ESC+LIF) or after LIF 
withdrawal for 10 days. Scale bar, 100 μm. 
Rapid and Potent Reprogramming of Human Somatic Cells Fused with S/G2-
Enriched Mouse ESCs 
To explore the possible mechanisms that underlie the improved reprogramming capacity of 
S/G2-enriched mouse ESCs we performed heterokaryon analyses using human B cells or 
human fibroblasts as targets (Figure 3A). This approach allows the earliest steps in 
reprogramming to be followed by employing a combination of species-specific antibodies, 
fluorescence in situ hybridization (FISH) probes, and RT-PCR primers to discriminate events 
that occur within individual mouse and human (somatic) nuclei after cellular fusion (Pereira 
et al., 2008; Piccolo et al., 2011). Human B cells were fused in a 1:1 ratio with 
unsynchronized or G1-, S-, G2-enriched mouse ESC fractions and expression of human 
pluripotency genes induced within these heterokaryons was compared using qPCR (Pereira 
and Fisher, 2009). Low levels of human OCT4 (POU5F1), NANOG, CRIPTO (Figure 3B), 
DNMT3b, REX1, FGFR1, FGF2, and TLE1 (Figure S3A) transcripts were detected 2 days 
after fusion with mouse ESCs (Pereira et al., 2010, 2008). The expression of human 
pluripotency genes was consistently higher in fusions performed with S/G2 ESCs as 
compared with either G1 or asynchronous cells (Figures 3B and andS3B,S3B, top). This 
enhanced reprogramming capacity of late S/G2 and G2-enriched mouse ESC fractions was 
reproducible and statistically significant (Figure 3C). To determine whether somatic targets 
other than lymphocytes were also susceptible, we also fused elutriated mouse ESC fractions 
with human fibroblasts. As shown in Figures 3D and andS3BS3B (lower), reprogramming of 
fibroblasts was also significantly enhanced following fusion with S/G2- and G2-enriched 
mESCs, as indicated by increased induction of human OCT4, NANOG, and CRIPTO 
transcripts. 
  
Figure 3 
 
Mouse ESCs Enriched for S and G2 Phases of the Cell Cycle Efficiently Reprogram Human B 
Lymphocytes and Fibroblasts in Heterokaryons 
(A) Experimental strategy for generating interspecies heterokaryons. Mouse ESCs (mESC) 
were fused in a 1:1 ratio with human B (hB) or human fibroblasts (hF) cells using PEG and 
cultured in ESC media supplemented with puromycin. 
 
(B) mESCs enriched according to cell-cycle stage (G1 = F8/9, G1/S = F11/12, S/G2 = F13/14, 
and G2/M = F15/16) were fused with hB cells and hES-specific gene expression was assessed 
using RT-qPCR and species-specific primers. Gene expression was calculated relative to 
GAPDH, using the human ESC cell line NCL1 as a positive control (Pereira et al., 2008). Two 
independent experiments are shown as examples. 
 
(C) The potency of mESCs to induce OCT4, NANOG, and CRIPTO expression from hB cells, 
2 and 3 days after fusion was assessed in seven independent experiments. Values were 
normalized to G2-enriched samples, error bars denote SE from the mean and values 
statistically different from G2 (p < 0.05; single sample t test) are marked with an asterisk. 
 
(D) In similar experiments using human fibroblasts as targets, human pluripotency gene 
induction was assessed (as above), and expression levels at day 0 (white bars) and day 4 (black 
bars) are shown. Error bars denote SE from the mean of three independent experiments, and 
asterisks indicate a significant difference with a p value (t test) of < 0.05. 
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Characterization of Elutriated mESC Fractions, Related to Figure 3 
(A) Induction of human pluripotency-associated genes was confirmed in heterokaryons formed 
between human B cells and G2-enriched mouse ESCs. This expression profile was similar to 
heterokaryons generated with ESCs (previously shown by Pereira et al. [2008]). Error bars 
indicate the SD of three independent experiments. 
 
(B) Induction of human OCT4, NANOG and CRIPTO transcripts from human B (day 3) and 
human Fibroblasts (day 4) was improved by fusing with S/G2 and G2-enriched mouse ESCs, 
as compared with either asynchronous or G1-enriched fractions. Gene expression was 
calculated relative to GAPDH and values represent data from 2-4 independent experiments. 
 
(C) Mouse pluripotency-associated gene transcript levels are similar throughout ESC cell-cycle 
progression. Quantitative RT-PCR analysis of the relative levels of gene expression in 
unsynchronized mouse ESCs and elutriated fractions enriched in G1 (F8-F9), S (F12), S/G2 
(F13) or G2/M (F16). Gene expression data was normalized to Gapdh and Ubc and error bars 
indicate the SD of 4-5 independent experiments. 
 
(D) Western blot analysis of mouse ESC extracts of unsynchronized (ESC, total) and 
populations enriched at different stages of the cell cycle (Fractions F8, F9, F12, F13, F16) in 
which antibodies to Oct4, Sox2 and c-Myc reveal the accumulation of Oct4 and Sox2 proteins 
at late stages of the cell cycle. CTCF and Lamin-B were used as loading controls. The red box 
enclose fractions with greater reprogramming potential to facilitate their comparison to extracts 
of unsynchronized ESCs. 
 
(E) Confocal images of mouse ESCs showing the cellular distribution of Oct4 and Sox2 
proteins (in green) during the cell cycle. Samples were separated by centrifugal elutriation 
(Fractions F8, F9, F12 and F13-16), subjected to IF and examined using identical laser settings 
for comparison. Among cells in fractions F13-16, 60% and 89% of cells showed moderate to 
intense labeling for Oct4 and Sox2, respectively. Background levels of Oct4 and Sox2 staining 
were seen in mitotic cells (15% and 12% of sample respectively). Nuclear DNA was stained 
with DAPI (blue) and scale bar, 5 μm. 
 
(F) Western blot analysis of nuclear insoluble (Ni) and cytoplasmic soluble (Cs) extracts of 
unsynchronized ESCs and samples separated by counterflow centrifugal elutriation, using 
antibodies to Oct4 and Sox2. Oct4 and Sox2 proteins remain nuclear and chromatin-bound 
throughout interphase, and their abundance increases in samples enriched for late stages of the 
ESC cell cycle. Tubulin and Lamin-B were used as loading controls for proteins associated 
with cytosolic (Cs) and nuclear fractions (Ni), respectively. 
To understand the basis of this improved reprogramming capacity we initially examined the 
possibility that factors that are known to potentiate or inhibit iPS-based reprogramming 
(Yamanaka and Blau, 2010) might fluctuate during ESC cell cycle. We were, however, 
unable to detect any significant changes in the levels of mouse Oct4, Klf4, Sox2, c-Myc, 
Nanog, p53, or p21 transcripts in cell-cycle-enriched mouse ESCs (Figure S3C) and protein 
levels remained unchanged for most candidates (Figure S3D). Although western blotting and 
immunofluorescence analysis showed slight increases in Oct4 and Sox2 levels upon cell-
cycle progression (Figures S3D and S3E; Tables S2A and S2B), careful comparison of 
unsynchronized and G2-enriched samples indicated broadly comparable levels in both 
(Figure S3D, red box). We did not see any experimental evidence that these factors were 
either prematurely dissociated from the chromatin or exported to the cytoplasm ahead of 
mitosis (Figure S3F). Likewise, Nanog expression, which displays a characteristic periodicity 
in ESC cultures (Chambers et al., 2007) and has been shown to enhance experimental 
reprogramming (Silva et al., 2006; Theunissen et al., 2011), was independent on ESC cell-
cycle stage (Table S2C; Figures S3C and S3D). 
S/G2 ESCs Induce Precocious Nucleotide Incorporation in Somatic Nuclei 
Shortly after Fusion 
An alternative explanation for the superior efficiency of S/G2-enriched ESCs to reprogram 
somatic cells is that S- or G2-phase cells were capable of inducing premature DNA synthesis 
and chromosome condensation in G1-phase targets (Johnson and Rao, 1970; Rao and 
Johnson, 1970) and that this may facilitate chromatin remodeling, DNA demethylation, and 
activation of critical genes, as has been previously suggested (De Carvalho et al., 2010; 
Mikkelsen et al., 2008). To examine this possibility, we fused human B and mouse ESCs in a 
1:1 ratio and after 24 hr applied a pulse of BrdU (45 min, 100 μM) to enumerate nuclei in 
these cultures that were undergoing DNA synthesis. Heterokaryons containing BrdU-labeled 
nuclei were then visualized by DAPI (blue), phalloidin (red), and anti-BrdU (green) 
costaining as shown in Figure 4A. Most heterokaryons contained BrdU-labeled nuclei 
(>85%) 1 day after fusion suggesting that nucleotide incorporation was relatively common in 
these heterokaryons. The amount (intensity) and distribution of BrdU labeling was similar to 
that seen in somatic and ESCs during S phase. To discriminate human nuclei that were 
incorporating BrdU (BrdU+ hB, green), we used gamma satellite probe (γ-satellite, red) to 
selectively mark mouse nuclei (Figure 4B). Using this approach, we scored BrdU+ hB in 
heterokaryons 24 hr after fusing human B cells with either unsynchronized or G2-enriched 
ESCs. Data from three independent experiments showed that a large proportion of 
heterokaryons formed with S/G2-enriched ESCs contained hB nuclei that incorporated BrdU 
(74%–86%, Table 1). In heterokaryons generated with unsynchronized mouse ESCs this 
proportion was lower (33%–48%). By comparison, heterokaryons formed with G1-enriched 
ESCs lacked widespread BrdU incorporation and failed to induce DNA synthesis within most 
human B cell targets (0/80, Table 1). These data show that ESCs in S/G2 phase of cell cycle 
induce precocious nucleotide incorporation within their somatic partners during early stages 
of heterokaryon formation. Consistent with this observation, ESC multikaryons that 
contained multiple human B cell nuclei (as illustrated in Figure S4A) usually showed 
coordinated BrdU labeling patterns in all somatic nuclei. BrdU incorporation by somatic 
nuclei in heterokaryons could be detected as soon as 5–6 hr after fusion with a pattern that 
was typical of early S phase (Figure S4B). Importantly, BrdU labeling was not seen in most 
hB homokaryons (Figure S4C) or within human B cells that had been engulfed by mouse 
ESCs but had retained a discrete cell wall (Figure S4D). This suggests that precocious DNA 
synthesis in lymphocyte nuclei is an early feature induced by ESC that requires the 
establishment of a shared cytoplasm. 
  
Figure 4 
 
Human Somatic Nuclei Undergo Precocious DNA Synthesis in Heterokaryons Formed 
with Mouse ESCs, and This Is Required for Successful Reprogramming 
(A) Confocal image of a representative heterokaryon (hB x mESC) at day 1, that was 
labeled for 45 min with BrdU and then stained to reveal incorporated BrdU (green), DAPI 
(blue), and Phalloidin (red). 
 
(B) Confocal Image showing simultaneous FISH detection of γ-satellite probe and BrdU 
labeling of hB × mESC heterokaryons at day 1, where γ-satellite (red) selectively labels 
mouse nuclei and BrdU incorporation (green) by hB nuclei is evident. The extent of BrdU 
incorporation by hB nuclei in heterokaryons formed with unsynchronized, S/G2-enriched 
or G1-enriched mESCs, was compared using these approaches and the results are shown 
in Table 1. DAPI nuclear staining is shown in blue. Scale bars, 2 μm. 
 
(C) Reprogramming of hB by mESCs was assayed 48 hr after heterokaryon formation in 
the absence (black) or presence (red) of 200 μM hydroxyurea (open triangle), 300 μM 
mimosine (open square), or 2 μg/ml aphidicolin (closed circle). Values are the mean and 
SE of five independent experiments. Differences between treated and untreated samples 
were significant with all drugs for OCT4, NANOG, and CRIPTO, and only with 
mimosine for DMNT3b (p value < 0.05, t test). DNA methylation at the OCT4 promoter 
was assessed 48 hr and 72 hr after fusion in the absence (black) or presence (red) of 
aphidicolin by HpaII digestion, where HpaII resistant fragments were quantified by qPCR 
using species-specific primers (blue bar indicate position), and normalized to undigested 
samples. Values shown are the mean and SD of four to six replicates in which the 
statistical significance is indicated by asterisks (p value < 0.005, t test). 
 
  
Figure S4 
 
BrdU Labeling of Somatic Nuclei during Reprogramming, Related to Figure 4 
(A) Confocal image of a mESC multikaryon (day 1) in which each of the 3 human 
nuclei showed similar BrdU-intense labeling pattern. 
 
(B) Confocal Image of a representative heterokaryon pulse labeled with BrdU (green) 6 
hr after PEG mediated cell fusion (hBxmESC) in which γ-satellite probe (red) was used 
to discriminate mouse ESCs. DAPI nuclear staining is shown in blue. 
 
(C) Homokaryons formed between human B cells failed to show BrdU incorporation in 
most cells (30/31). Scale bars in A-C indicate 2μm. 
 
(D) BrdU incorporation is not induced in hB cells that retain intact cell membranes after 
fusion with mESCs. A confocal image taken 24 hr after fusion of hB and mESCs (1:1), 
in which some human B cells (DAPI-diffuse, small nuclei) were engulfed within mouse 
ESCs (punctate DAPI labeling of larger nuclei) but retain their discrete cellular 
membranes, revealed by Phalloidin stain (red). BrdU incorporation in these 
‘encapsulated’ human B cells was not detected (0/108). Scale bar, 5μm. 
 
(E) A representative confocal image showing a single Z-section of a hBxmESC 
heterokaryon (24 hr after fusion), pulsed with EdU (100 μM, 45 min prior to fixation) 
(white), and processed for DNA FISH analysis using probes for human α-globin (GG1, 
green) and β-globin (ME2.5, red) and DAPI (blue, merged image) as described 
previously (Brown et al., 2001). In the human nucleus both α-globin alleles appeared as 
doublet signals consistent with replication having occurred (the second allele is not 
shown here). Both β-globin signals (a late replicating locus) appeared as singlet signals. 
Scale bar, 5 μm. 
 
(F) Confocal images taken 24 hr after fusion of human fibroblasts (hF) and mESCs (in a 
1:1 ratio) in which BrdU incorporation (green, a 45 min-pulse) by somatic hF nuclei 
(DAPI diffuse, arrow left) was detected (BrdU+, arrow right). Scale bar, 5μm. 
 
(G) Confocal images of a representative hFxmESC heterokaryon 72 hr after fusion, 
showing doublet signals for human HUWE1 probe (green, arrowed) consistent with 
prior DNA replication (sample size > 100, scale bar, 5 μm). 
 
  
Table 1 
Incorporation of BrdU by Human B Nuclei Contained within 1 Day Heterokaryons Formed 
with Mouse ESCs 
 BrdU
+ hB Sample Size %
Experiment 1 
 
hB × unsynchronized mESC 8 24 33 
hB × S/G2-enriched mESC 30 35 86 
 
Experiment 2 
 
hB × unsynchronized mESC 11 23 48 
hB × S/G2-enriched mESC 14 19 74 
 
Experiment 3 
 
hB × unsynchronized mESC 10 30 33 
hB × S/G2-enriched mESC 27 35 77 
hB × G1-enriched mESC 0 80 <1.3 
 
Heterokaryons between human B (hB) and mouse ESC (1:1) were 
cultured for 1 day and pulse labeled with BrdU (100 μM/45 min), 
and resulting nucleotide incorporation in hB (BrdU+hB) was 
assessed as shown in Figure 4. Heterokaryons formed with S/G2-
enriched mESCs contained a higher proportion of hB nuclei that 
incorporated BrdU than heterokaryons generated with 
unsynchronized mESCs (p value < 0.003). 
  
 
To determine whether nucleotide incorporation by somatic nuclei was likely to reflect 
widespread DNA repair or genuine DNA replication, we performed DNA FISH analysis and 
scored doublet FISH signals 24 hr after fusion. Using genomic probes for human α-globin 
and β-globin (loci that replicate early and late in B cells, respectively) (Brown et al., 2001) 
together with EdU (to visualize nucleotide incorporation), we routinely detected doublet 
signals for α-globin in human B nuclei 24 hr after fusion (24/25 nuclei, 98%), whereas β-
globin appeared as singlet signals (exemplified in the mid-S-phase nucleus shown in 
Figure S4E). As doublets reflect the separation of newly replicated sister chromatids during S 
phase (Azuara et al., 2003; Selig et al., 1992) these data are consistent with human somatic 
nuclei undergoing DNA replication. Parallel experiments using human fibroblasts (IMR90, 
hF) showed widespread BrdU incorporation by somatic nuclei a day after fusion with 
unsynchronized ESCs (Figure S4F), with doublet FISH signals (HUWE1) clearly evident at 
days 2–3 (Figure S4G). These data confirmed human DNA replication in ESC-heterokaryons 
ahead of nuclear fusion. 
DNA Replication Is Critical for Initiating Successful Reprogramming of 
Somatic Nuclei toward Pluripotency in ESC-Derived Heterokaryons 
To evaluate whether DNA synthesis was required to initiate pluripotent gene expression from 
somatic nuclei, we fused human B cells and mouse ESCs and then monitored human 
pluripotent gene induction following treatment with agents that block DNA synthesis. 
Treatment of heterokaryons with aphidicolin (a drug that inhibits DNA polymerase activity), 
mimosine (that arrests cells in late G1) or with hydroxyurea (to prevent late origin firing) for 
48 hr severely compromised the induction of a panel of human pluripotency genes as 
compared with untreated controls (Figure 4C, top). DNA demethylation at endogenous 
human OCT4 alleles was evident in untreated cultures, as indicated by increased sensitivity to 
HpaII digestion (Figure 4C, bottom, black). However, in parallel cultures in which DNA 
polymerase activity was inhibited by aphidicolin treatment, we detected no corresponding 
change in sensitivity of the OCT4 locus (Figure 4C, bottom, red). Taken together, these data 
suggested that precocious DNA synthesis within somatic nuclei was critical for remodeling 
and demethylating the human OCT4 locus prior to its reactivation in heterokaryons. 
Oct4 Re-Expression and Precocious DNA Synthesis 
The incidence of precocious DNA synthesis among successfully reprogrammed ESC 
heterokaryons was evaluated in BrdU tracing experiments, using Oct4-GFP as a reporter. 
Briefly, mouse B cells carrying Oct4-GFP were fused with nonsynchronized ESCs and pulse 
labeled with BrdU (100 μM, 45 min) at different times early after fusion (at 6, 18, or 24 hr, or 
double-pulsed at 6 and 18 hr), washed and returned to culture. Two to 3 days after fusion 
heterokaryons that contained “reprogrammed lymphocytes” were identified on the basis of 
GFP re-expression and then examined to ask whether these cells retained BrdU that had been 
acquired during the time window of the pulse. A schematic representation of this experiment 
is depicted in Figure 5A. As shown in Figure 5B and illustrated in Figure 5C, most Oct4-GFP 
positive heterokaryons (green) identified 2-3 days after fusion had incorporated BrdU (red) 
within the first few hours of fusion. Specifically, we demonstrated that about a third of all 
successfully reprogrammed cells were marked by BrdU applied 6 hr postfusion and about 
two thirds of all successfully reprogrammed cells were marked by BrdU applied 18 hr 
postfusion. By applying a double pulse of BrdU at 6 and 18 hr after fusion, virtually all 
(90%) successfully reprogrammed B cells identified on the basis of Oct4 re-expression, were 
shown to have undergone DNA synthesis within a day of fusion with ESCs. 
 
  
Figure 5 
 
 
Somatic Nuclei that Re-Express Oct4 Show Widespread Nucleotide Incorporation 
within 24 hr of Heterokaryon Formation with ESCs 
(A) Experimental strategy used to assess the kinetics of BrdU incorporation in 
successfully reprogrammed mB cells. Heterokaryons formed between mouse ESCs and 
B cells were pulse labeled (45 min) with BrdU at different times points after fusion (6, 
18, or 24 hr) in separate experiments or pulse labeled twice at 6 and 18 hr after fusion in 
a single experiment. BrdU incorporation was analyzed among successful reprogrammed 
mouse B cells identified on the basis of Oct4-GFP re-expression at 2–3 days after 
fusion. 
 
(B) Reprogrammed cells (33%–37%) had already incorporated BrdU during a pulse 
labeling applied 6 hr after fusion, a percentage that increased to 62% and 76% when 
fused cells were pulse labeled at 18 and 24 hr, respectively. Sequential pulse labeling at 
6 and 18 hr demonstrates that the majority of successfully reprogrammed heterokaryons 
(90%) incorporated BrdU within a day of fusion. 
 
(C) Confocal image of a successfully reprogrammed mouse B cell (mB, arrow) 
identified on the basis of Oct4-GFP (green) re-expression at 48 hr, that had incorporated 
BrdU (red) during a pulse applied 6 hr after PEG-mediated fusion with mESCs (mESC, 
arrow). Scale bar, 5 μm. 
Discussion 
Here we provide quantitative evidence that dominant reprogramming of somatic cells by 
ESCs is enhanced using S/G2-enriched samples. This extends claims made from hybrid 
studies (Sullivan et al., 2006) showing that the potency of S/G2 ESCs occurs in 
heterokaryons when pluripotent gene expression is initiated. We found no evidence that the 
improved reprogramming efficiency of S/G2 ESCs was due to reprogramming factors present 
in cells at later stages of the cell cycle or their “release” into the cytoplasm prior to mitotic 
chromosome condensation. Rather, our data indicate that ESCs in S/G2 induce B cells or 
fibroblasts to undergo DNA synthesis within a day of fusion and heterokaryon formation. 
This is important for reprogramming as inhibitors of DNA synthesis such as hydroxyurea, 
mimosine and aphidicolin, blocked pluripotent gene induction in heterokaryons. We also 
found that virtually all heterokaryons that re-expressed a somatically derived Oct4-GFP 
transgene showed evidence of premature DNA synthesis occurring within the first day after 
fusion. Collectively, this indicates that early DNA synthesis is a critical feature of successful 
stem cell fusion-mediated reprogramming that has not been fully appreciated until now. 
Interestingly, reprogramming studies using nuclear transfer have indicated that cell-cycle 
synchronization between the donor nucleus and recipient cytoplasm appears to be important 
(Campbell and Alberio, 2003; Campbell et al., 1996) and the ability of mammalian 
embryonic cytoplasm to support reprogramming has been shown to fluctuate with the cell 
cycle (Egli et al., 2007). Although synchronization of the cell cycle is not sufficient to 
determine successful reprogramming in heterokaryons per se (i.e., G1-phase ESCs do not 
efficiently reprogram G1-phase B cells), our data may highlight the importance of cell-cycle 
“compatibility” between nuclei inducing and nuclei undergoing reprogramming. Consistent 
with classical studies of cell-cycle progression (Blow and Laskey, 1988) and the cell fusion 
experiments reported by Johnson and Rao (1970) and Rao and Johnson (1970), we showed 
that fusing S/G2-phase ESCs with somatic cells induced precocious DNA synthesis in 
somatic nuclei. As 70%–75% of cultured human B cells are in G1, most of these targets 
would be expected to be already licensed for DNA replication (reviewed in Blow and Dutta, 
2005) and therefore susceptible to S-phase promotion by S/G2 ESCs. In this regard, recent 
experiments using Xenopus egg extracts at the metaphase (M phase) stage have also shown 
that M phase can both drive DNA synthesis and improve reprogramming efficiency in 
nuclear transfer and in iPS assays (Ganier et al., 2011). iPS-based studies have, in addition, 
indicated that reprogramming can be accelerated by DNA synthesis and cell division (Hanna 
et al., 2009) as well as by agents that inhibit histone deacetylation (Huangfu et al., 2008) or 
interfere with the maintenance of DNA methylation (De Carvalho et al., 2010; Feng et al., 
2009; Mikkelsen et al., 2008). 
The demonstration that nucleotide incorporation is widespread among somatic nuclei in 
heterokaryons raises the possibility that DNA demethylation of genes that are critical 
for reprogramming, such as Oct4 (Simonsson and Gurdon, 2004) could be achieved by 
replication-dependent (passive) means. Previous studies have implicated AID-mediated 
deamination in active DNA demethylation in heterokaryons (Bhutani et al., 2010), and 
Gadd45 (growth arrest and DNA damage 45 protein) in active DNA demethylation during 
differentiation and stress response (Niehrs and Schäfer, 2012). In preimplantation embryos, 
both active and passive mechanisms have been implicated in genome-wide DNA 
demethylation in which Tet3-mediated conversion of 5-methylcytosine to 5-hydroxy-
methylcytosine appears to be central (Gu et al., 2011; Inoue and Zhang, 2011). In ESCs, Tet1 
and Tet2 family members are actively expressed (Ficz et al., 2011; Wu and Zhang, 2011; Xu 
et al., 2011) and recent studies have implicated Tet2 and Parp1 in iPS-based reprogramming 
(Doege et al., 2012). In an accompanying manuscript (Piccolo et al., 2013) we show that Tet1 
and Tet2 participate in ESC- and EG-mediated heterokaryon reprogramming and are required 
to reset DNA methylation within the somatic genome. Interestingly, as conversion of 5-
methylcytosine to 5-hydroxy-methylcytosine can occur in the presence of drugs that inhibit 
DNA replication (Piccolo et al., 2013), it seems likely that both active (DNA replication-
independent) and passive (DNA replication-dependent) mechanisms may contribute to 
pluripotent reprogramming in ESC heterokaryons. This duality may be helpful in reconciling 
some of the conflicting data arising from reprogramming studies in vivo, as well as providing 
an explanation for the recent proposal that heterokaryon-mediated reprogramming is 
mechanistically biphasic (Foshay et al., 2012). 
The observation that early DNA synthesis is prevalent in somatic nuclei fused with ESCs is 
however at odds with a previous report in which BrdU incorporation was not seen in 
heterokaryons formed between human fibroblasts and mouse ESCs (Bhutani et al., 2010). 
Although we do not at present have an explanation for this, it is unlikely that this discrepancy 
is due to the use of different somatic cells or to interspecies incompatibilities as we observed 
extensive BrdU incorporation using both human and mouse fibroblasts. In our hands AID 
expression (a putative mediator of 5-methylcytosine deamination) was not detectable in fused 
or unfused cells, as has been reported by others (Foshay et al., 2012). Regardless of the 
explanation for these differences, our study offers a fresh perspective on how reprogramming 
works as well as providing a simple and reliable method for enriching ESCs at different cell-
cycle stages. This will be important for future reprogramming studies and to better 
understand the importance of the unusual cell-cycle structure in pluripotent stem cell self-
renewal. 
 
Experimental Procedures 
Cell Culture 
E14Tg2a Hprt−/− (E14) mouse ESCs, EBV-transformed human B cells, and Abelson-
transformed mouse B cells were cultured as described previously (Pereira et al., 2008). 
Quantitative RT-PCR Analysis 
RNA extraction and RT-qPCR was carried out as described previously (Pereira et al., 2008; 
primer sequences shown in Table S1). 
Centrifugal Elutriation 
Counter-flow centrifugal elutriation was carried out using JE-5.0 elutriator system (Beckman 
Coulter) in combination with MasterFlex peristaltic pump (Cole-Parmer Instrument) as 
described by Banfalvi (2008) and detailed in Extended Experimental Procedures. 
Extended Experimental Procedures 
Centrifugal Elutriation of mESCs 
Mouse ESCs (E14tg2A) were trypsinized and 3-5x108 resuspended in 10ml of elutriation 
buffer (1% FCS and 0.1% EDTA in PBS). Cells were gently passed through a syringe with an 
18G needle and loaded into the chamber (Sanderson elutriation chamber; Beckman Coulter) 
at a flow rate of 6ml/min and a rotor speed of 1,800 r.p.m., 4°C. Subpopulations of cells were 
eluted by gradually increasing (1ml/min) the flow rate. For E14tg2A cells, enrichment of 
cells at G1, S or G2/M is achieved at 8-9ml/min, 12-14ml/min and 16-17ml/min, 
respectively. Slight variation in the cellular composition of fractions between experiments 
can occur as a consequence of the number of loaded cells and temperature of the elutriation 
media. When a standard chamber was used instead of a Sanderson chamber, centrifugation 
speed and flow rates were adjusted as suggested by the manufacturer (Beckman Coulter). At 
least 150ml was collected per fraction, and samples were collected into FCS, where 
appropriate, to enhance cell viability. To determine cell-cycle stages, cells were fixed in 70% 
Ethanol and their DNA content was assessed by propidium iodide (PI) staining, using 
FACScalibur (BD Biosciences) and CellQuest software. 
Heterokaryons Immunofluorescence Assays 
Heterokaryon immunofluorescence analysis used the following approach; elutriated and 
unsynchronized mouse ESCs were washed twice with PBS, resuspended in KO-DMEM 
medium supplemented with 10% FCS and plated in 0.1% gelatin coated coverslips. Once 
mouse ESCs attached, hB cells (previously washed twice with PBS) were gently resuspended 
in 1 ml of 37°C pre-warmed PEG and poured over the ESCs monolayer (mES:hB ratio 1:2). 
After 2 min incubation at 37°C, 2 ml of serum-free KO-DMEM was added and cells were 
centrifuged at 1,500 rpm for 5 min. Fused cells were cultured in KO-DMEM plus 2% horse 
serum and LIF for 3hr at 37°C. Finally, the medium was removed and cells were cultured 
under conditions promoting the maintenance of undifferentiated mouse ES cells. 
Protein Extraction from Nuclear and Cytoplasmic Fractions 
Cell pellets were resuspended in ice-cold lysis buffer (10mM HEPES, pH 7.9, 10mM KCl, 
1.5mM MgCl2, 0.34M Sucrose, 1mM DTT, 0.1% Triton X, 1.5mM PMSF and Protease 
inhibitors cocktail (Roche)) for 5 min on ice and centrifuged at 1,300 g for 5 min, 4°C. 
The cytoplasmic fraction (supernatant) was collected, washed once with lysis buffer without 
Triton-X and centrifuged for 10 min at 14,000 g, 4°C. The nuclear pellet was resuspended in 
nuclear lysis buffer (3mM EDTA, 0.2mM EGTA, 1mM DTT, 1.5 mM PMSF and Protease 
inhibitors cocktail (Roche)), incubated for 30 min on ice and centrifuged at 1,700 g for 5 min, 
4°C. The pellet was washed once in nuclear lysis buffer and resuspended in 2x Laemmli 
buffer. The extracts were sonicated 3 x for 10 s each at 4°C, gently vortexed, incubated for 
5 min at 95°C and chilled on ice. Protein extracts from 0.15 × 106 cells were loaded per lane. 
Primers Used in Bisulfite Sequencing Analysis 
Bisulfite-converted genomic DNA was used as template to amplify the endogenous (Oct4) 
and transgenic (GOF18ΔPE) (tOct4) Oct4 locus using the following primers: Oct4 forward, 
5′- TGGGTTGAAATATTGGGTTTATTT-3′ and reverse, 5′-
TGGGTTGAAATATTGGGTTTATTT-3′; tOct4 forward, 5′-
GGGGTTAGAGGTTAAGGTTAGAGG-3′ and reverse, 5′- 
ACCAAAATAAACACCACCCC-3′. 
Primers Used in HpaII Resistance Assay 
HpaII resistant fragments were quantified by qPCR using species-specific primers that 
flanked a HpaII/MspI sensitive site in the promoter region of OCT4. HpaII-sensitive site 
forward, 5′-GTGTCTGTGGAAGGGGAAAA-3′ and reverse, 5′-
AGTTTCTGTGGGGGACCTG-3′; HpaII-insensitive site forward, 5′-
CCACTAGCCTTGACCTCTGG-3′ and reverse, 5′- CCACCATTAGGCAAACATCC-3′. 
Heterokaryons and Hybrid Assays 
Heterokaryons were generated by fusing mouse ESCs enriched at different cell-cycle stages 
and human B cells (mESC/hB ratio 1:1) using polyethylene glycol (PEG) as described 
previously (Pereira and Fisher, 2009). Nonfused mouse ESCs were eliminated by 
supplementing the medium with HAT (20 μM hypoxanthine, 0.08 μM aminopterin, and 
3.2 μM thymidine; Sigma) or Puromycin (1μg/ml; Sigma). Nonfused hB cells were, where 
appropriate, eliminated using ouabain (10−5 M; Sigma) applied at least 6–18 hr after cell 
fusion, and details of immunofluorescence analyses are provided in Extended Experimental 
Procedures. 
Hybrids between mESCs (enriched either in G1, S, S/G2, or G2/M) and puromycin-resistant 
(Puro+) mB cells were generated by PEG-mediated fusion (mESC/mB ratio 1:1) (Pereira and 
Fisher, 2009). Nonfused mESCs were eliminated by the addition of Puromycin (1 μg/ml; 
Sigma), and alkaline phosphatase staining was performed on colonies 12 days after fusion. 
Protein Extraction and Western Blot Analysis 
Whole-cell protein extracts were prepared with Laemmli buffer, and nuclear and cytoplasmic 
protein extracts were prepared as described in Extended Experimental Procedures. Western 
blot analysis were performed using the following antibodies: goat polyclonal to Oct4 
(1:2,000; sc-8628, Santa Cruz Biotechnology), Sox2 (1:2,000; sc-17320, Santa Cruz 
Biotechnology), and LaminB (1:5,000; sc-6216, Santa Cruz Biotechnology); Mouse 
monoclonal to c-Myc (9E10) (1:2000; sc-40, Santa Cruz Biotechnology) and Tubulin 
(1:2,000; T9026 Sigma-Aldrich); rabbit polyclonal to CTCF (1:500; ab70303 Abcam). The 
secondary antibodies used were anti-mouse HRP (1:2000, GE Healthcare), anti-rabbit HRP 
(1:5,000, GE Healthcare), and anti-goat HRP (1:2000, sc-2020 Santa Cruz Biotechnology). 
The Amersham ECL plus kit (GE Healthcare) was used for detection. 
Immunofluorescence, FISH, and BrdU detection 
Immunofluorescence analysis was performed (Terranova et al., 2006) using goat polyclonal 
to Oct4 (1:200, sc-8628, Santa Cruz Biotechnology) and Sox2 (1:200, sc-17320, Santa Cruz 
Biotechnology), and secondary antibodies at 1:400 dilution (Molecular Probes). BrdU 
incorporation and detection was performed in low light conditions as described by Azuara 
et al. (2003) where heterokaryons were grown on gelatinized coverslips for 1 day, pulse 
labeled with 100 μM BrdU added to the media for 45 min, and fixed with 2% 
paraformaldehyde in PBS for 20 min at room temperature. Blocking and washing was 
performed as described by Terranova et al. (2006). Phalloidin-Alexa Fluor 568 (Invitrogen 
A12380, diluted 1:50 in blocking buffer) and/or BrdU-FITC (Becton-Dickinson 347583, 
diluted 1:4 in blocking buffer) were applied for 30 min before final washes and mounting in 
Vector-shield containing 0.5 mg/ml DAPI (Sigma D9542). Three-dimensional DNA FISH for 
human α- and β-globin were performed as described (Brown et al., 2001) on heterokaryons 
growing on 0.2% gelatin-coated coverslips. To codetect EdU incorporated as a 45 min pulse 
label before cell fixation, the Click-iT kit (Invitrogen) was used according to manufacturer’s 
instructions following the sodium borohydride step. Coverslips were subsequently washed 
with PBS, blocked as described in the 3D FISH protocol before postfixation and DNA 
denaturation, and kept in the dark following detection of EdU. 
Bisulfite Sequencing Analysis 
Bisulfite treatment of genomic DNA was performed with the EZDNA methylation kit 
(Zymogenetics). Bisulfite-converted DNA was used as template to amplify endogenous 
(Oct4) and transgenic Oct4 (GOF18ΔPE) (tOct4) (primers are available in Extended 
Experimental Procedures). PCR products were cloned into pCR2 vector (Invitrogen) and 
randomly sequenced. 
HpaII Resistance Assay 
Genomic DNA (5 μg/sample) was digested with HpaII (50 U, NEB), with MspI (100 U, 
NEB), or left untreated (undigested) for 4 hr at 37°C, followed by proteinase K treatment 
(30 min at 40°C). HpaII-resistance was quantified using qPCR and primers that flanked an 
HpaII/MspI-sensitive site in the promoter region of OCT4. Ct values were normalized to a 
region lacking an HpaII/MspI site and to untreated controls. HpaII resistance was calculated 
as the percentage difference between HpaII (test) and MspI (total) digested samples. Primers 
are available in Extended Experimental Procedures. 
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